ATRA vs INCR

The Advanced Deterministic Scorecard reveals a critically weak financial health profile with a Piotroski F-Score of just 2/9, indicating severe operational and financial distress. Despite a current price of $5.22 appearing low relative to an intrinsic value estimate of $20.02, the company exhibits alarming fundamentals including negative operating margin (-102.72%), collapsing revenue (YoY growth: -91.40%), and a bearish insider selling trend. While recent earnings surprises have been positive, the long-term financial instability, lack of reliable Altman Z-Score, and deteriorating cash position overshadow any valuation appeal. The stock's technical trend is deeply bearish, and analyst consensus is only a 'hold' with limited coverage, further undermining confidence.

InterCure Ltd. exhibits severe financial distress as evidenced by a weak Piotroski F-Score of 2/9, indicating poor operational efficiency and financial health. Despite a very low Price-to-Book ratio of 0.10, the company is trapped in a catastrophic long-term price decline, losing over 91% of its value over five years. Negative profit margins and crashing EPS growth suggest that the low valuation is a value trap rather than a bargain. The lack of analyst coverage and a 0/100 technical trend further reinforce a bearish outlook.